AIKI - NVAX Stock Alert: 14 Things to Know as the Novavax Vaccine Faces the FDA Today
InvestorPlace - Stock Market News, Stock Advice & Trading Tips
- Novavax (NVAX) is taking part in a meeting with the FDA today.
- This concerns its EUA for its Covid-19 vaccine.
- The company is hoping that the FDA will approve its vaccine.
Novavax (NASDAQ:NVAX) stock is in the news today as investors prepare for the results from the company’s meeting with the U.S. Food and Drug Administration (FDA).
Let’s go over everything investors in NVAX stock need to know about today’s meeting.
- This meeting will have the FDA reviewing Novavax’s Emergency Use Application (EUA) for its Covid-19 vaccine.
- The EUA has Novavax seeking the use of the vaccine in adults.
- There’s a few things that investors will want to keep an eye out for during the meeting.
- Among these is the FDA’s response to a myocarditis issue.
- The NVAX vaccine’s trail results include a 0.007% incident of heart inflammation.
- This was pointed out by the FDA last week and that news sent shares of NVAX stock falling.
- Another sticking point to keep in mind is chemistry, manufacturing, and controls (CMC) preparation.
- This is another concern the FDA has had about the NVX-CoV2373 vaccine.
- It’s actually this that has delayed the meeting for the EUA for so long.
- Another thing to note is that NVAX’s vaccine is different from other Covid-19 shots.
- While the major focus has been on the new mRNA vaccines, Novavax went with a more traditional vaccine.
- This has it using the same technology that’s been used for Hepatitis B and influenza.
- That means the company could see interest in the vaccine from those that have been skeptical of the mRNA ones.
- Either way, investors are hoping the FDA will approve the EUA, which could be a catalyst for NVAX stock.
NVAX stock is currently halted as of this writing.
There’s more stock market news to read about below!
InvestorPlace has all the latest stock news for traders to dive into! Among that is what’s going on with shares of GitLab (NASDAQ:GTLB), AeroClean (NASDAQ:AERC), and AIkido Pharma (NASDAQ:AIKI) stock today. You can catch up on that news at the following links!
More Tuesday Stock Market News
- GitLab (GTLB) Stock Pops 20% on Q1 Earnings Beat
- AERC Stock Is in the Spotlight After AeroClean Receives FDA Clearance
- Why Is AIkido Pharma (AIKI) Stock Up 1,400%?
On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines.
More From InvestorPlace
- Stock Prodigy Who Found NIO at $2… Says Buy THIS
- It doesn’t matter if you have $500 in savings or $5 million. Do this now.
- Get in Now on Tiny $3 ‘Forever Battery’ Stock
- Early Bitcoin Millionaire Reveals His Next Big Crypto Trade “On Air”
The post NVAX Stock Alert: 14 Things to Know as the Novavax Vaccine Faces the FDA Today appeared first on InvestorPlace.